Fulcrum Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 26, 2025. The filing covers the election of directors, executive compensation advisory votes, frequency of compensation votes, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
- Director Elections: Stockholders elected Katina Dorton, Robert Gould, and Kate Haviland as Class III directors for three-year terms ending in 2028.
- Katina Dorton: 44,618,582 votes For; 1,601,489 votes Withheld.
- Robert J. Gould: 43,847,378 votes For; 2,372,693 votes Withheld.
- Kate Haviland: 33,203,495 votes For; 13,016,576 votes Withheld.
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- Votes For: 46,099,800
- Votes Against: 111,967
- Abstain: 8,304
- Compensation Vote Frequency: Stockholders selected a one-year frequency for future non-binding advisory votes on executive compensation.
- One Year: 44,882,180 votes
- Two Years: 51,488 votes
- Three Years: 1,273,388 votes
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 49,513,190
- Votes Against: 22,808
- Abstain: 1,628
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors. Management commentary is limited to the Board's determination to solicit annual advisory votes on executive compensation consistent with the stockholder results.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director Kate Haviland (13,016,576) compared to other nominees.
- Confirm the Board's commitment to annual Say-on-Pay votes as mandated by the stockholder vote.
- Note the high level of support for the ratification of Ernst & Young LLP with minimal opposition.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.